Horizon Pharma to Be Added to NASDAQ Biotechnology Index
DEERFIELD, IL -- (Marketwired) -- 12/17/13 -- Horizon Pharma, Inc.
(NASDAQ: HZNP), today announced that it has been selected for
addition to the NASDAQ Biotechnology Index effective prior to the
market open on Monday, December 23, 2013.
The NASDAQ Biotechnology Index is designed to track the performance
of a set of NASDAQ-listed securities classified according to the
Industry Classification Benchmark (ICB) as either Biotechnology or
Pharmaceuticals. These companies must meet eligibility criteria that
include a minimum market capitalization of $200 million and minimum
average daily trading volume of 100,000 shares, amongst other
requirements. The Index Securities are evaluated semi-annually in May
and November and serve as the basis for the iShares NASDAQ
Biotechnology Index Fund (NASDAQ: IBB). For more information about
the NASDAQ Biotechnology Index, including eligibility criteria, visit
About Horizon Pharma
Horizon Pharma, Inc. is a commercial stage,
specialty pharmaceutical company that markets DUEXIS(R),
RAYOS(R)/LODOTRA(R) and VIMOVO(R), which target unmet therapeutic
needs in arthritis, pain and inflammatory diseases. The Company's
strategy is to develop, acquire or in-license additional innovative
medicines where it can execute a targeted commercial approach among
specific target physicians such as primary care physicians,
orthopedic surgeons, and rheumatologists, while taking advantage of
its commercial strengths and the infrastructure the Company has put
in place. For more information, please visit www.horizonpharma.com.
Robert J. De Vaere
Executive Vice President and Chief Financial Officer
Press spacebar to pause and continue. Press esc to stop.